H.C. Wainwright notes that Eli Lilly (LLY) announced that it was acquiring Point Biopharma (PNT) for an aggregate amount of approximately $1.4B. The firm believes this acquisition is relevant because it continues to point to Big Pharma’s interest in radiopharmaceuticals, and thinks that Actinium (ATNM) is a prime candidate for acquisition. Recall that Iomab-B has already delivered positive pivotal data and the Actimab-A program continues to deliver potentially transformative data. With a cash runway into 2025, H.C. Wainwright believes Actinium is positioned well to explore multiple options in its Iomab-B commercialization decisions. The firm has a Buy rating on Actinium’s shares with a price target of $50.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ATNM:
- Eli Lilly deal for Point puts radiopharma names in spotlight
- Point Biopharma deal reads positively to radiopharma names, says B. Riley
- Actinium presents updated survival data from Phase 2b trial of Actimab-A
- Actinium Pharmaceuticals initiated with a Buy at HSBC
- Actinium price target lowered to $50 from $53 at H.C. Wainwright
